Synthaverse S.A. (WSE: SVE)

Market Cap	310.25M
Revenue (ttm)	62.66M
Net Income (ttm)	4.45M
Shares Out	70.27M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,937
Open	4.350
Previous Close	4.355
Day's Range	4.330 - 4.415
52-Week Range	3.552 - 5.930
Beta	1.13
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 20, 2024

About Synthaverse

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunog...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 239
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SVE

Financial Performance

In 2023, Synthaverse's revenue was 58.61 million, an increase of 16.32% compared to the previous year's 50.38 million. Earnings were 4.76 million, a decrease of -21.76%.